Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients

2004 ◽  
Vol 56 (6) ◽  
pp. 418-426 ◽  
Author(s):  
Linda L. Carpenter ◽  
Francisco A. Moreno ◽  
Mitchel A. Kling ◽  
George M. Anderson ◽  
William T. Regenold ◽  
...  
2002 ◽  
Vol 17 ◽  
pp. 136
Author(s):  
R. Armitage ◽  
M. Husain ◽  
R. Hoffmann ◽  
A.J. Rush

1991 ◽  
Vol 21 (3) ◽  
pp. 613-618 ◽  
Author(s):  
Alec Roy ◽  
Judith Dejong ◽  
Thomas Ferraro

SYNOPSISThe inhibitory neurotransmitter gamma-aminobutyric acid (GABA) has been implicated in the pathophysiology of depression. Therefore, we examined cerebrospinal fluid (CSF) levels of GABA in depressed patients (N = 25) and normal controls (N = 20). There was no significant difference between the groups. However, among the depressed patients the subgroup of unipolar melancholic patients (N = 13) had significantly lower CSF levels of GABA than the rest of the depressed patients (N = 12). There was no significant difference for CSF levels of GABA between depressed patients who were (N = 14) or were not (N = 11) cortisol non-suppressors. It was of interest that among the controls there was a significant negative correlation between CSF levels of GABA and CSF levels of norepinephrine.


2019 ◽  
Author(s):  
Kevin P. Cheng ◽  
Sarah K. Brodnick ◽  
Stephan L. Blanz ◽  
Weifeng Zeng ◽  
Jack Kegel ◽  
...  

AbstractVagal nerve stimulation (VNS) is an FDA approved treatment method for intractable epilepsy, treatment resistant depression, cluster headaches and migraine with over 100,000 patients having received vagal nerve implants to date. Moreover, evidence in the literature has led to a growing list of possible clinical indications, with several small clinical trials applying VNS to treat conditions ranging from neurodegenerative diseases to arthritis, anxiety disorders, and obesity. Despite the growing list of therapeutic applications, the fundamental mechanisms by which VNS achieves its beneficial effects are poorly understood and an area of active research. In parallel, the glymphatic and meningeal lymphatic systems have recently been proposed and experimentally validated to explain how the brain maintains a healthy homeostasis without a traditionally defined lymphatic system. In particular, the glymphatic system relates to the interchange of cerebrospinal fluid (CSF) and interstitial fluid (ISF) whose net effect is to wash through the brain parenchyma removing metabolic waste products and misfolded proteins from the interstitium. Of note, clearance is sensitive to adrenergic signaling, and a primary driver of CSF influx into the parenchyma appears to be cerebral arterial pulsations and respiration. As VNS has well-documented effects on cardiovascular and respiratory physiology as well as brain adrenergic signaling, we hypothesized that VNS delivered at clinically derived parameters would increase CSF influx in the brain. To test this hypothesis, we injected a low molecular weight (3 kD) lysine-fixable fluorescent tracer (TxRed) into the CSF system of mice with a cervical vagus nerve cuff implant and measured the amount of CSF penetrance following VNS. We found that the clinical VNS group showed a significant increase in CSF dye penetrance as compared to the naïve control and sham groups. This study demonstrates that VNS therapeutic strategies already being applied in the clinic today may induce intended effects and/or unwanted side effects by altering CSF/ISF exchange in the brain. This may have broad ranging implications in the treatment of various CNS pathologies.One Sentence SummaryCervical vagus nerve stimulation using clinically derived parameters enhances movement of cerebrospinal fluid into the brain parenchyma presenting a previously unreported effect of vagus nerve stimulation with potential clinical utility.


2020 ◽  
Vol 13 (4) ◽  
pp. 1024-1030 ◽  
Author(s):  
Kevin P. Cheng ◽  
Sarah K. Brodnick ◽  
Stephan L. Blanz ◽  
Weifeng Zeng ◽  
Jack Kegel ◽  
...  

2007 ◽  
Vol 31 (11) ◽  
pp. 1756-1759 ◽  
Author(s):  
J V Pardo ◽  
S A Sheikh ◽  
M A Kuskowski ◽  
C Surerus-Johnson ◽  
M C Hagen ◽  
...  

2007 ◽  
Vol 1 (5) ◽  
pp. 771-779 ◽  
Author(s):  
Jamie S. Bodenlos ◽  
Samet Kose ◽  
Jeffrey J. Borckardt ◽  
Ziad Nahas ◽  
Darlene Shaw ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document